Literature DB >> 28825207

Infectious complications in multiple myeloma receiving autologous stem cell transplantation in the past 10 years.

Hyunkyung Park1, Jeonghwan Youk1, Hak Ro Kim1, Youngil Koh1,2,3, Ji Hyun Kwon1,4, Sung-Soo Yoon1,2,3, Seonyang Park1,2,3, Pyoeng Gyun Choe5, Nam Joong Kim5, Myoung-Don Oh5, Wan Beom Park6, Inho Kim7,8,9.   

Abstract

Infection is one of the main causes of early-treatment mortality in multiple myeloma (MM) patients during autologous stem cell transplantation (autoSCT). In the present study, we sought to determine the incidence of, and risk factors for, infection during hospital stays after autoSCT. We retrospectively evaluated 324 autoSCT events that occurred in 285 MM patients between 2006 and 2015, and reviewed the clinical characteristics of patients and history of infections. Sixty-eight infection events occurred, including bacteremia (24), other bacterial infections (7), as well as infections caused by Cytomegalovirus (17), Herpes simplex virus (12), Varicella zoster virus (3), Aspergillus (3) and Pneumocystis jiroveci (2). There was no significant difference in number of infections in the 2006-2010 and 2011-2015 periods (P = 0.194). Risk factors for bacteremia included higher beta-2 microglobulin levels at diagnosis [≥3.5 mg/L; adjusted odds ratio (aOR) 3.544 (95% CI 1.070-11.736), P = 0.038] and previous bortezomib treatment [aOR 4.270 (95% CI 1.389-13.125), P = 0.011]. In-hospital mortality occurred in 1.2% of all cases and all were infection-related. In conclusion, infection was the main cause of in-hospital mortality in patients who underwent autoSCT. Bacteremia was the most common type of microbiologically confirmed infection, and was associated with higher beta-2 microglobulin levels and previous bortezomib treatment.

Entities:  

Keywords:  Beta-2 microglobulin; Bortezomib; Infection; Multiple myeloma; Transplantation

Mesh:

Substances:

Year:  2017        PMID: 28825207     DOI: 10.1007/s12185-017-2313-2

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  42 in total

1.  Bortezomib-associated late hepatitis B reactivation in a case of multiple myeloma.

Authors:  Selvihan Beysel; Zeynep Arzu Yeğın; Münci Yağci
Journal:  Turk J Gastroenterol       Date:  2010-06       Impact factor: 1.852

2.  A direct role for IFN-gamma in regulation of Th1 cell development.

Authors:  L M Bradley; D K Dalton; M Croft
Journal:  J Immunol       Date:  1996-08-15       Impact factor: 5.422

3.  Incidence of hospital-acquired infection and length of hospital stay.

Authors:  B H Tess; H M Glenister; L C Rodrigues; M B Wagner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-02       Impact factor: 3.267

4.  International staging system for multiple myeloma.

Authors:  Philip R Greipp; Jesus San Miguel; Brian G M Durie; John J Crowley; Bart Barlogie; Joan Bladé; Mario Boccadoro; J Anthony Child; Herve Avet-Loiseau; Jean-Luc Harousseau; Robert A Kyle; Juan J Lahuerta; Heinz Ludwig; Gareth Morgan; Raymond Powles; Kazuyuki Shimizu; Chaim Shustik; Pieter Sonneveld; Patrizia Tosi; Ingemar Turesson; Jan Westin
Journal:  J Clin Oncol       Date:  2005-04-04       Impact factor: 44.544

5.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.

Authors:  Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard
Journal:  Clin Infect Dis       Date:  2011-02-15       Impact factor: 9.079

6.  The proteasome inhibitor bortezomib enhances the susceptibility to viral infection.

Authors:  Michael Basler; Christoph Lauer; Ulrike Beck; Marcus Groettrup
Journal:  J Immunol       Date:  2009-10-19       Impact factor: 5.422

7.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

Authors:  Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

8.  IL-17 and TNF-α sustain neutrophil recruitment during inflammation through synergistic effects on endothelial activation.

Authors:  Gabriel K Griffin; Gail Newton; Margarite L Tarrio; De-xiu Bu; Elena Maganto-Garcia; Veronica Azcutia; Pilar Alcaide; Nir Grabie; Francis W Luscinskas; Kevin J Croce; Andrew H Lichtman
Journal:  J Immunol       Date:  2012-05-07       Impact factor: 5.422

9.  Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy.

Authors:  Ji-Won Kim; Chang-Ki Min; Yeung-Chul Mun; Yong Park; Byung Soo Kim; Seung-Hyun Nam; Youngil Koh; Ji-Hyun Kwon; Pyoeng Gyun Choe; Wan Beom Park; Inho Kim
Journal:  J Clin Virol       Date:  2015-10-24       Impact factor: 3.168

10.  Infections in Hospitalised Patients with Multiple Myeloma: Main Characteristics and Risk Factors.

Authors:  Toni Valković; Vedrana Gačić; Jelena Ivandić; Božo Petrov; Renata Dobrila-Dintinjana; Elizabeta Dadić-Hero; Antica Načinović-Duletić
Journal:  Turk J Haematol       Date:  2015-09       Impact factor: 1.831

View more
  5 in total

1.  Addition of doxycycline to ciprofloxacin for infection prophylaxis during autologous stem cell transplants for multiple myeloma.

Authors:  J M Sivik; J Davidson; C M Hale; J J Drabick; G Talamo
Journal:  Support Care Cancer       Date:  2018-03-21       Impact factor: 3.603

2.  Impact of COVID-19 in patients with multiple myeloma based on a global data network.

Authors:  J Martinez-Lopez; G Hernandez-Ibarburu; R Alonso; J M Sanchez-Pina; I Zamanillo; N Lopez-Muñoz; Rodrigo Iñiguez; C Cuellar; M Calbacho; M L Paciello; R Ayala; N García-Barrio; D Perez-Rey; L Meloni; J Cruz; M Pedrera-Jiménez; P Serrano-Balazote; J de la Cruz
Journal:  Blood Cancer J       Date:  2021-12-10       Impact factor: 11.037

3.  Multiple Myeloma Index for Risk of Infection.

Authors:  Valkovic T; Gacic V; Nacinovic-Duletic A
Journal:  J Cancer       Date:  2018-06-04       Impact factor: 4.207

4. 

Authors:  Hans-Jürgen Laws; Ulrich Baumann; Christian Bogdan; Gerd Burchard; Maximilian Christopeit; Jane Hecht; Ulrich Heininger; Inken Hilgendorf; Winfried Kern; Kerstin Kling; Guido Kobbe; Wiebe Külper; Thomas Lehrnbecher; Roland Meisel; Arne Simon; Andrew Ullmann; Maike de Wit; Fred Zepp
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2020-05       Impact factor: 1.513

5.  Early infection in post-autologous hematopoietic stem cell transplant patients: Princess Noorah Oncology Center experience.

Authors:  Roaa S Gassas; Ahmed N Absi; Abdulrahman A Alghamdi; Ahmed S Alsaeed; Sameer M Alamoudi; Ihab Y Hemaidi; Majed D Alahmadi; Walaa A Rajkhan; Mannar M Khalil; Saleem K Dadah; Ahmed S Higazi; Amani S Ahmed
Journal:  Saudi Med J       Date:  2021-08       Impact factor: 1.422

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.